This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

With Promising Results, AstraZeneca Targets Mutated Lung Cancer And Rival Clovis Drug

AMSTERDAM ( TheStreet) -- With promising early-stage study results presented this weekend, AstraZeneca's (AZN - Get Report) experimental lung cancer drug AZD9291 looks to be a potent tumor-shrinking competitor for Clovis Oncology's (CLVS) CO-1686.

The AstraZeneca and Clovis drugs are both designed to be effective against non-small cell lung cancer that no longer responds to currently approved therapies because of a genetic mutation known as T790M.

There are no drugs currently approved for T790M-positive lung cancer, which affects approximately 15,500 people in the U.S. The mutation is more prevalent in Asian lung cancer patients, according to Stifel analyst Brian Klein.

Preliminary results from an ongoing phase I study of AstraZeneca's AZD9291 demonstrated partial tumor shrinkage in 12 of 26 patients, or a response rate of 46%. Twelve of these patients had tumors that carried the T790M mutation and seven reported partial tumor shrinkage -- a response rate of 58% in T790M-positive tumors. A mild, grade 1 rash was the most commonly reported side effect, but did not lead to any treatment discontinuations.

AstraZeneca presented the AZD9291 study results at the European Cancer Congress (ECCO) 2013. The study is enrolling additional patients and higher doses of AZD9291 are being tested.

"If the partial responses seen for AZD9291 in NSCLC patients with T790M are shown to be durable, and the data can be reproduced in a multi-center setting then I would not be surprised if AZD9291 obtained breakthrough status from the FDA," said Pieter Droppert of the Biotech Strategy Blog, who is in Amsterdam covering ECCO 2013 with collaborator and noted cancer drug analyst Sally Church.

Last June, Clovis shares doubled to $75 on the presentation of early-stage data on CO-1686 in which three of four patients with T790M-positive lung cancer reported partial tumor shrinkage. The CO-1686 phase I study continues with updated results expected to be presented at a lung cancer meeting at the end of October.

More recently, Clovis shares have fallen to $60.59 on unconfirmed reports that the company put itself up for sale but could not find a buyer. Still, Clovis shares have more than tripled in value this year. The company is also developing a second drug targeted against breast and ovarian cancer.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AZN $68.43 -2.16%
CLVS $74.23 -0.96%
AAPL $124.43 -1.54%
FB $82.22 -1.18%
GOOG $548.00 -0.73%

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs